Rabeprazole and Tricyclic Antidepressant Combination

This entry describes the combination of Rabeprazole, a proton pump inhibitor (PPI) used to reduce stomach acid production [1], and Tricyclic Antidepressants (TCAs), a class of medications primarily used for major depressive disorder that work by blocking serotonin and norepinephrine reuptake [3, 5]. This combination, specifically rabeprazole and amitriptyline (a TCA), has been studied for treating functional chest pain (FCP) that did not respond to standard PPI therapy [2]. A randomized trial showed potential benefits of combining rabeprazole (20 mg/day) with low-dose amitriptyline (10 mg at bedtime) compared to double-dose rabeprazole (20 mg twice daily) in improving global symptom scores in patients with refractory FCP [2]. While TCAs are typically used for depression, they can have effects relevant to pain modulation and functional gastrointestinal disorders, making their combination with acid suppression agents like rabeprazole potentially useful for conditions requiring both approaches [2].